Benign prostatic hyperplasia (BPH) is an enlargement of the prostate gland and the most common benign tumor found in man. BPH causes an obstruction of the flow of urine through the urethra. Treatment is only necessary if symptoms become bothersome. By age 80, some 40 percent of men experience BPH symptoms severe enough to require treatment.
Inflammation is a significant finding in a variety prostate diseases including prostatitis, BPH, and prostate cancer. Our department studies microbial and autoimmune mediated inflammation and innate and adaptive immune mechanisms in prostate disease. Projects in the lab use a combination of in vitro studies, animal models and clinical specimen assays to examine questions of interest such as the role of chemokines and T cells in chronic pelvic pain.
Faculty treat patients at the Feinberg-affiliated care sites. Currently the main treatment options for BPH are watchful waiting, medication, surgery (generally a TURP, or transurethral resection of the prostate), or intermittent catheterization.
Geoffery Engel, MD
Sarah C. Flury, MD
Matthias Hofer, MD/PhD
Stephanie J. Kielb, MD